<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107436">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01717963</url>
  </required_header>
  <id_info>
    <org_study_id>2011-002858-31</org_study_id>
    <secondary_id>204725-1</secondary_id>
    <nct_id>NCT01717963</nct_id>
  </id_info>
  <brief_title>Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway</brief_title>
  <acronym>NTX-SBX</acronym>
  <official_title>Optimal Prevention of Overdose Deaths and Opioid Relapse Following Discharge: A Multi-Center RCT of Naltrexone Versus Buprenorphine in Norway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Royal Norwegian Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ostfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persons dependent on opioids like heroin, morphine, or codeine have a high risk of overdose
      and overdose death. This risk is elevated even further following discharge from treatment or
      correctional institutions where patients have been detoxified. At the moment,
      state-of-the-art treatment is based on maintaining the dependence on opioids by daily intake
      of opioid medications like methadone or buprenorphine. Recently, a medication containing the
      blocking agent naltrexone was approved in the US; this does not maintain dependence but
      instead blocks heroin and other opioids for 28 days after intramuscular administration. This
      study will conduct a 12-week randomized comparison of naltrexone intramuscular suspension
      (XL-NTX) with daily buprenorphine-naloxone in OMT. Medication will start preceding discharge
      from a treatment or correctional facility to participating catchment regions in Norway. The
      main hypotheses are that XL-NTX will do equally well as - or better than - OMT on the
      proportion of biological samples negative for opioids, retention, self-reported use of
      alcohol and illicit drugs. Following the 12-week randomized period, there will be a 36-week
      period where participants can receive the study medication of their choice. In addition to
      the randomized groups, persons who fulfill inclusion criteria but decline medical treatment
      for opioid dependence will be asked to participate in an unrandomized control group without
      study medication and with less frequent data collection. After the end of the study, data
      from national registry databases can be collected for a further 12 months on outcomes such
      as recidivism, mortality and morbidity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of biological samples negative/positive for opioid agonists</measure>
    <time_frame>Week 1-12 post discharge</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention</measure>
    <time_frame>First 12 weeks post discharge</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Week 1-48</time_frame>
    <safety_issue>No</safety_issue>
    <description>A mortality comparison is made between medicated groups (pooled together) and the non-medicated group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Use of other substances of abuse</measure>
    <time_frame>Week 1-48</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mental health</measure>
    <time_frame>Week 1-12 or 1-48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-reported mental health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatic health</measure>
    <time_frame>Week 1-12 or 1-48 post discharge</time_frame>
    <safety_issue>No</safety_issue>
    <description>Self-reported and/or assessed by study personnel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychosocial problems</measure>
    <time_frame>Week 1-12, Week 1-48, &amp; Wk 49-100</time_frame>
    <safety_issue>No</safety_issue>
    <description>Psychosocial problems like recidivism, employment, family problems. Self-reported or registry-based.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Naltrexone intramuscular suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine-naloxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Voluntarily unmedicated</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this group are opioid dependent but express no interest in medical treatment at time of inclusion. They consent to a limited collection of data in the study and are not randomized to a study medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone intramuscular suspension</intervention_name>
    <description>A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered</description>
    <arm_group_label>Naltrexone intramuscular suspension</arm_group_label>
    <other_name>Long-acting naltrexone</other_name>
    <other_name>Extended-release naltrexone</other_name>
    <other_name>XR-NTX</other_name>
    <other_name>Vivitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine-naloxone</intervention_name>
    <description>Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).</description>
    <arm_group_label>Buprenorphine-naloxone</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Opioid dependence (DSM-IV TR)

          -  Age 18 or above

          -  Applied &amp; Approved for Norway's national OMT program

          -  Discharge within 30 days of inclusion from a controlled environment; e.g. inpatient
             treatment or correctional (prison) facility

          -  Voluntarily seeking treatment for opioid dependence

        Exclusion Criteria:

          -  Pregnant or breast-feeding

          -  Acute or recurring severe psychiatric disorder, e.g. psychosis, suicidality

          -  Serious debilitation of liver or renal function (e.g. Child-Pugh level C)

          -  Use of excluded medication

          -  Known intolerance to study drugs or their ingredients

          -  Employment in firm manufacturing one of the study drugs or close relation to such
             person
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Tanum, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oslo, Norway</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Tanum, MD, PhD</last_name>
    <email>lars.tanum@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikolaj Kunøe, PhD</last_name>
    <email>nikolaj.kunoe@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Oslo</city>
        <state>Akershus</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Tanum, MD, PhD, DmSci</last_name>
      <email>lars.tanum@ahus.no</email>
    </contact>
    <investigator>
      <last_name>Lars Tanum, MD, PhD, DmSci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zill-e-Huma Latif, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arild Opheim</last_name>
      <email>arild.opheim@helse-bergen.no</email>
    </contact>
    <investigator>
      <last_name>Ola Jøsendal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sverre Nesvåg, PhD</last_name>
      <email>ness@sus.no</email>
    </contact>
    <investigator>
      <last_name>Kristian Larsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vestfold Hospital Trust</name>
      <address>
        <city>Tonsberg</city>
        <state>Vestfold</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamni Sharma, MD</last_name>
      <email>kamsha@siv.no</email>
    </contact>
    <investigator>
      <last_name>Kamni Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Avdeling for Rus og Avhengighet</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Live Sanderud, MD</last_name>
      <email>l.s.stavseth@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Peter Krajci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Live S Stavseth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Østfold Hospital Trust</name>
      <address>
        <city>Fredrikstad</city>
        <state>Østfold</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merete Møller, RN</last_name>
      <email>merete.moller@so-hf.no</email>
    </contact>
    <investigator>
      <last_name>Arild Schillinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://naltrekson.no</url>
    <description>Website for the Univ of Oslo Naltrexone study group (in Norwegian)</description>
  </link>
  <link>
    <url>http://www.seraf.uio.no/</url>
    <description>Webpage of the study Sponsor: The Norwegian Centre for Addiction Research, Univ of Oslo</description>
  </link>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 3, 2013</lastchanged_date>
  <firstreceived_date>October 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oslo</investigator_affiliation>
    <investigator_full_name>Lars Tanum</investigator_full_name>
    <investigator_title>National Coordinating Investigator (PI)</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
